Now approved
for an expanded indication
Learn more DUP.21.07.0103

Discover
a path to
asthma
control

Discover a path to
asthma control

DUPIXENT IS THE ONLY DUAL INHIBITOR OF IL-4 AND IL-13
SIGNALING, ADDRESSING TWO KEY SOURCES OF
TYPE 2 INFLAMMATION IN ASTHMA.1

The mechanism of action of dupilumab in asthma
has not been definitively established.1

Explore the efficacy and safety
#1 biologic currently prescribed by allergists2

Significant efficacy across multiple endpoints

UP TO
81%
REDUCTION
IN SEVERE
EXACERBATIONS1,a
See Results
UP TO
480mL
IMPROVEMENT
IN LUNG FUNCTION1,b
See Results
 
86%
OF PATIENTS
REDUCED OR
ELIMINATED OCS DOSE3,c
See Results

aWith DUPIXENT 300 mg + SOC (n=64) vs placebo + SOC (n=68) in annualized rate of severe exacerbations through Week 24 in patients with baseline blood eosinophils
≥300 cells/μL (Trial 1, secondary endpoint).

bAt Week 52 with DUPIXENT 300 mg + SOC (n=277) vs 230 mL improvement with placebo + SOC (n=142) in patients with baseline blood eosinophils ≥300 cells/μL (Trial 2, secondary endpoint).

cAt Week 24 with DUPIXENT 300 mg + SOC (n=103) vs 68% with placebo + SOC (n=107) (Trial 3, ITT population).

EOS, eosinophils; ITT, intention-to-treat; OCS, oral corticosteroid; SOC, standard of care.

EXPLORE LONG-TERM
EFFICACY AND SAFETY
DUP.21.09.0495

Mechanism of Action (MOA)

DUPIXENT is a dual inhibitor of IL‑4 and IL-13 signaling, impacting 2 of the sources that mediate allergic and eosinophilic inflammation.1

Explore the MOA

The mechanism of action of dupilumab in asthma has not been definitively established.1

Multiple Administration Options

Work with your patients to decide how to administer DUPIXENT: either administer at home or you administer in the office.1

See Dosing and Administration

A patient or caregiver may inject DUPIXENT after training in subcutaneous injection technique.1

Safety Data

View safety data across clinical trials.

DUPIXENT MyWay is a patient support program that can help enable access to DUPIXENT and offers financial assistance for eligible patients, one-on-one nursing support, and more.

Learn how we can help

DUPIXENT MyWay
ENROLLMENT FORMS

FOR ALLERGISTS
English Enrollment Form
Spanish Enrollment Form
FOR ENT SPECIALISTS/
PULMONOLOGISTS
English Enrollment Form
Spanish Enrollment Form
NO BIOMARKER
TESTING REQUIRED
for DUPIXENT

for 99% of OCS-dependent asthma patients who are commercially insured4

Check Formulary Status in Your Area

See the insurance coverage status, prior authorization, and step edit information for DUPIXENT.

Look up coverage

References:

  1. DUPIXENT Prescribing Information.
  2. Data on file, Sanofi US. IQVIA National Source of Business; data through September 2020.
  3. Rabe KF, Nair P, Brusselle G, et al. Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma. N Engl J Med. 2018;378(26):2475-2485.
  4. The Dedham Group Quality of Access Tracking Report, April 2021.

Important Safety
Information and Indication

CONTRAINDICATION: DUPIXENT is contraindicated in patients with known hypersensitivity to dupilumab or any of its excipients.

WARNINGS AND PRECAUTIONS

Hypersensitivity: Hypersensitivity reactions, including generalized urticaria, rash, erythema nodosum, erythema multiforme, anaphylaxis, and serum sickness or serum sickness-like reactions, were reported in <1% of subjects who received DUPIXENT in clinical trials. If a clinically significant hypersensitivity reaction occurs, institute appropriate therapy and discontinue DUPIXENT.

Eosinophilic Conditions: Patients being treated for asthma may present with serious systemic eosinophilia sometimes presenting with clinical features of eosinophilic pneumonia or vasculitis consistent with eosinophilic granulomatosis with polyangiitis (EGPA), conditions which are often treated with systemic corticosteroid therapy. These events may be associated with the reduction of oral corticosteroid therapy. Physicians should be alert to vasculitic rash, worsening pulmonary symptoms, cardiac complications, and/or neuropathy presenting in their patients with eosinophilia. Cases of eosinophilic pneumonia were reported in adult patients who participated in the asthma development program and cases of vasculitis consistent with EGPA have been reported with DUPIXENT in adult patients who participated in the asthma development program as well as in adult patients with co-morbid asthma in the chronic rhinosinusitis with nasal polyposis development program. A causal association between DUPIXENT and these conditions has not been established.

Acute Asthma Symptoms or Deteriorating Disease: Do not use DUPIXENT to treat acute asthma symptoms, acute exacerbations, acute bronchospasm or status asthmaticus. Patients should seek medical advice if their asthma remains uncontrolled or worsens after initiation of DUPIXENT.

Risk Associated with Abrupt Reduction of Corticosteroid Dosage: Do not discontinue systemic, topical, or inhaled corticosteroids abruptly upon initiation with DUPIXENT. Reductions in corticosteroid dose, if appropriate, should be gradual and performed under the direct supervision of a physician. Reduction in corticosteroid dose may be associated with systemic withdrawal symptoms and/or unmask conditions previously suppressed by systemic corticosteroid therapy.

Parasitic (Helminth) Infections: It is unknown if DUPIXENT will influence the immune response against helminth infections. Treat patients with pre-existing helminth infections before initiating therapy with DUPIXENT. If patients become infected while receiving treatment with DUPIXENT and do not respond to anti-helminth treatment, discontinue treatment with DUPIXENT until the infection resolves. Helminth infections (5 cases of enterobiasis and 1 case of ascariasis) were reported in pediatric patients 6 to 11 years old in the pediatric asthma development program.

ADVERSE REACTIONS: The most common adverse reactions (incidence ≥1%) in patients with asthma are injection site reactions, oropharyngeal pain, and eosinophilia.

DRUG INTERACTIONS: Avoid use of live vaccines in patients treated with DUPIXENT.

USE IN SPECIFIC POPULATIONS

  • Pregnancy: A pregnancy exposure registry monitors pregnancy outcomes in women exposed to DUPIXENT during pregnancy. To enroll or obtain information call 1‑877‑311‑8972 or go to https://mothertobaby.org/ongoing-study/dupixent/. Available data from case reports and case series with DUPIXENT use in pregnant women have not identified a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. Human IgG antibodies are known to cross the placental barrier; therefore, DUPIXENT may be transmitted from the mother to the developing fetus.
  • Lactation: There are no data on the presence of DUPIXENT in human milk, the effects on the breastfed infant, or the effects on milk production. Maternal IgG is known to be present in human milk. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for DUPIXENT and any potential adverse effects on the breastfed child from DUPIXENT or from the underlying maternal condition.

Please see accompanying full Prescribing Information


Indication

DUPIXENT is indicated as an add-on maintenance treatment of patients 6 years and older with moderate-to-severe asthma characterized by an eosinophilic phenotype or with oral corticosteroid dependent asthma. Limitation of Use: DUPIXENT is not indicated for the relief of acute bronchospasm or status asthmaticus.